NCT07943221
Study Evaluating Safety & Tolerability of Migaldendranib in US Healthy Volunteers
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Secondary (6)
Show 1 moreShow less
Arms and interventions
Participants receive MGB 200 mg Formulation 1 administered subcutaneously once weekly on Days 1, 8, and 15 to evaluate safety, tolerability, and pharmacokinetics.
Participants receive MGB 200 mg Formulation 2 administered subcutaneously once weekly on Days 1, 8, and 15 to evaluate safety, tolerability, and pharmacokinetics.
Participants receive MGB 400 mg administered subcutaneously once weekly on Days 1, 8, and 15 following Safety Review Committee approval.
This optional arm will be used if recommended by the Safety Review Committee. Dosage TBD.
Drugs: Weekly subcutaneous administration of Migaldendranib (MGB)
Sites
1 site in 1 country
- Medpace Clinical Pharmacology UnitCincinnati, Ohio, United States